| Name | Title | Contact Details |
|---|---|---|
Robert Freeberg |
Vice President Procurement | Profile |
Mark Christopulos |
R&D Portfolio - Senior Director | Profile |
Philippe Samama |
VP, New Product Strategy & Planning | Profile |
Nathalie Dubois-Stringfellow |
Senior Vice President, Product Development and Management | Profile |
Mark Edwards |
Senior Director, Supply Chain Management | Profile |
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.
Madeira Therapeutics is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tactical Therapeutics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
zacharon is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Unigene Laboratories, Inc. (Unigene) is a biopharmaceutical company engaged in the research, production and delivery of small proteins, referred to as peptides, for medical use. The Company has a manufacturing technology for producing many peptides